Department of Biochemistry and Molecular Biology, Poznan University of Medical Sciences, 6 Swiecickiego Street, 60-781, Poznan, Poland.
Department of Animal Genetics and Breeding, National Research Institute of Animal Production, Balice, Poland.
J Hum Genet. 2018 Apr;63(4):397-406. doi: 10.1038/s10038-017-0397-4. Epub 2018 Feb 5.
Although the aetiology of non-syndromic cleft lip with or without cleft palate (nsCL/P) has been studied extensively, knowledge regarding the role of genetic factors in the pathogenesis of this common craniofacial anomaly is still limited. We conducted a follow-up association study to confirm that CDKAL1 nucleotide variants identified in our genome-wide association study (GWAS) for nsCL/P are associated with the risk of this anomaly. In addition, we performed a sequence analysis of the selected CDKAL1 exons. A mega-analysis of the pooled individual data from the GWAS and a replication study revealed that six out of thirteen CDKAL1 variants were positively replicated and reached the threshold of statistical significance (P < 3.85E-03). They represented a single association signal and were located within the fifth intron of CDKAL1. The strongest individual variant was rs9356746 with a P value = 5.71E-06 (odds ratio (OR) = 1.60, 95% confidence interval (CI): 1.30-1.97). Sequencing analysis did not reveal any pathogenic mutations of this gene. This study provides the first evidence that chromosomal region 6p22.3 is a novel susceptibility locus for nsCL/P. The location of the risk variants within the CDKAL1 intronic sequence containing enhancer elements predicted to regulate the SOX4 transcription may suggest that SOX4, rather than CDKAL1, is a potential candidate gene for this craniofacial anomaly.
尽管非综合征性唇裂伴或不伴腭裂(nsCL/P)的病因已被广泛研究,但遗传因素在这种常见颅面畸形发病机制中的作用仍知之甚少。我们进行了一项随访关联研究,以确认我们在 nsCL/P 的全基因组关联研究(GWAS)中鉴定的 CDKAL1 核苷酸变体与该异常的风险相关。此外,我们还对选定的 CDKAL1 外显子进行了序列分析。GWAS 和复制研究的个体数据合并后的 mega 分析表明,13 个 CDKAL1 变体中有 6 个呈阳性复制,达到统计学意义的阈值(P < 3.85E-03)。它们代表单一关联信号,位于 CDKAL1 的第五个内含子内。最强的个体变体是 rs9356746,其 P 值为 5.71E-06(优势比(OR)= 1.60,95%置信区间(CI):1.30-1.97)。测序分析未发现该基因的任何致病突变。这项研究首次提供了证据,表明 6p22.3 染色体区域是 nsCL/P 的一个新的易感位点。风险变体位于包含增强子元件的 CDKAL1 内含子序列内,这些增强子元件预测可调节 SOX4 转录,这表明 SOX4 而不是 CDKAL1 可能是这种颅面畸形的潜在候选基因。